BioKier

BioKier, a clinical-stage pharmaceutical company, was founded in 2008 by George Szewczyk and Roger D. Nolan.

The company is headquartered in Chapel Hill, North Carolina, and is focused on developing oral treatments for diabetes and related metabolic disorders. The founders, George Szewczyk, who serves as the CEO, and Roger D. Nolan, the President and COO, have guided the company in its mission to provide non-invasive solutions for patients.

BioKier's business model revolves around the development and commercialization of proprietary drugs and medical foods. The company operates in the highly competitive pharmaceutical market, with a specific focus on the ever-growing diabetes care sector. Its approach to commercialization is through the 505(b)(2) New Drug Application (NDA) pathway, which allows for a potentially faster and less costly route to market by relying on existing data for previously approved drugs.

The core of BioKier's product pipeline is an oral medication designed to manage blood glucose and lipid levels. This treatment is notable for its mechanism of action, which is intended to replicate the beneficial effects of metabolic surgery, but without the need for an invasive procedure. The company has developed a proprietary delivery system to ensure the targeted release of the active ingredients in the gastrointestinal tract. This innovative approach could offer a significant improvement in the quality of life for individuals with diabetes and related conditions.

Keywords: diabetes, metabolic disorders, oral therapeutics, pharmaceutical, 505(b)(2) NDA, lipid management, glucose control, medical food, clinical-stage, drug development